As an active member of an international team developing ways to deliver oligonucleotides (GENEGUT) we cheer for novel approaches in this field.
Now, WACKER, Corden Pharma – A Full-Service CDMO, Ludwig-Maximilian University, and Humboldt University use AI in drug development: they train machine learning algorithms for the formulation of RNA actives.
The aim is to develop a new generation of lipid nanoparticles (LNPs), which are a key component of RNA-based pharmaceuticals. Based on these formulations, a machine learning algorithm is to be trained that automatically identifies the best constituents for new RNA formulations – as yet a particularly time-consuming and costly development stage. The three-year project will start on April 1, 2023, and is receiving funding of some €1.4 million from the German Federal Ministry for Economic Affairs and Energy.
See the full press release here
